CRSP - CRISPR Therapeutics AG
NASDAQ
->
Healthcare
->
Biotechnology
Zug,
Switzerland
Type: Equity
CRSP price evolution
CRSP
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $401.07 | $539.6 | $456.6 | $356.12 |
| Short term investments | $1304.21 | $1212.06 | $1323.31 | $1538.76 |
| Net receivables | $200 | $70 | ||
| Inventory | ||||
| Total current assets | $1908.08 | $1760.59 | $1859.57 | $1907.97 |
| Long term investments | $1.97 | $4.9 | $6.32 | |
| Property, plant & equipment | $305.94 | $312.34 | $318.52 | $315.54 |
| Goodwill & intangible assets | $0.02 | $0.03 | $0.04 | $0.06 |
| Total noncurrent assets | $321.49 | $326.24 | $337.44 | $336.4 |
| Total investments | $1306.19 | $1212.06 | $1328.21 | $1545.08 |
| Total assets | $2229.57 | $2086.83 | $2197.01 | $2244.36 |
| Current liabilities | ||||
| Accounts payable | $38.15 | $26.15 | $27.59 | $45.15 |
| Deferred revenue | $18.12 | $19.32 | $12.32 | $12.32 |
| Short long term debt | $15.63 | $15 | $14.83 | $15.72 |
| Total current liabilities | $108.79 | $111.23 | $132.84 | $146.79 |
| Long term debt | $223.01 | $226.59 | $230.34 | $224.55 |
| Total noncurrent liabilities | $237.98 | $247.8 | $248.15 | $242.67 |
| Total debt | $238.63 | $241.59 | $245.18 | $240.27 |
| Total liabilities | $346.77 | $359.04 | $380.99 | $389.47 |
| Shareholders' equity | ||||
| Retained earnings | -$999.7 | -$1089.05 | -$976.89 | -$899.15 |
| Other shareholder equity | $1.91 | -$6.8 | -$8.91 | -$9.39 |
| Total shareholder equity | $1882.8 | $1727.79 | $1816.03 | $1854.9 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $401.07 | $223.52 | $939.94 | $1185.47 |
| Short term investments | $1304.21 | $1603.43 | $1456.1 | $521.71 |
| Net receivables | $200 | $0.3 | $0.14 | |
| Inventory | ||||
| Total current assets | $1908.08 | $1853.03 | $2417.51 | $1716.62 |
| Long term investments | $1.97 | $53.13 | ||
| Property, plant & equipment | $305.94 | $320.56 | $312.04 | $93.03 |
| Goodwill & intangible assets | $0.02 | $0.07 | $0.13 | $0.18 |
| Total noncurrent assets | $321.49 | $390.03 | $334.36 | $111.35 |
| Total investments | $1306.19 | $1656.56 | $1456.1 | $521.71 |
| Total assets | $2229.57 | $2243.06 | $2751.88 | $1827.97 |
| Current liabilities | ||||
| Accounts payable | $38.15 | $27.43 | $14.82 | $9.09 |
| Deferred revenue | $18.12 | $12.32 | $13.33 | $14.12 |
| Short long term debt | $15.63 | $15.84 | $12.16 | $11.36 |
| Total current liabilities | $108.79 | $121.11 | $119.88 | $94.26 |
| Long term debt | $223.01 | $228.18 | $212.87 | $50.07 |
| Total noncurrent liabilities | $237.98 | $246.47 | $232.53 | $69.47 |
| Total debt | $238.63 | $244.02 | $225.03 | $61.43 |
| Total liabilities | $346.77 | $367.58 | $352.42 | $163.73 |
| Shareholders' equity | ||||
| Retained earnings | -$999.7 | -$846.09 | -$195.91 | -$573.58 |
| Other shareholder equity | $1.91 | -$15.65 | -$5.07 | -$0.08 |
| Total shareholder equity | $1882.8 | $1875.48 | $2399.46 | $1664.23 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $201.21 | $70 | $100 | |
| Cost of revenue | ||||
| Gross Profit | $201.21 | $70 | $100 | |
| Operating activities | ||||
| Research & development | $115.14 | $114.12 | $146.19 | $142.13 |
| Selling, general & administrative | $16.48 | $18.29 | $19.03 | $22.36 |
| Total operating expenses | $131.62 | $132.41 | $165.22 | $164.49 |
| Operating income | $69.58 | -$132.41 | -$95.22 | -$64.49 |
| Income from continuing operations | ||||
| EBIT | $89.58 | -$111.74 | -$76.82 | -$51.74 |
| Income tax expense | $0.23 | $0.41 | $0.92 | $1.32 |
| Interest expense | ||||
| Net income | ||||
| Net income | $89.35 | -$112.15 | -$77.74 | -$53.06 |
| Income (for common shares) | $89.35 | -$112.15 | -$77.74 | -$53.06 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $371.21 | $1.2 | $914.96 | $0.72 |
| Cost of revenue | ||||
| Gross Profit | $371.21 | $1.2 | $914.96 | $0.72 |
| Operating activities | ||||
| Research & development | $517.58 | $571.89 | $438.63 | $266.95 |
| Selling, general & administrative | $76.16 | $102.46 | $102.8 | $88.21 |
| Total operating expenses | $593.74 | $674.36 | $541.43 | $355.15 |
| Operating income | -$222.54 | -$673.16 | $373.53 | -$354.44 |
| Income from continuing operations | ||||
| EBIT | -$150.72 | -$650.5 | $379.53 | -$348.06 |
| Income tax expense | $2.89 | -$0.33 | $1.87 | $0.81 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$153.61 | -$650.17 | $377.66 | -$348.87 |
| Income (for common shares) | -$153.61 | -$650.17 | $377.66 | -$348.87 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $89.35 | -$112.15 | -$77.74 | -$53.06 |
| Operating activities | ||||
| Depreciation | $4.9 | $4.92 | $4.96 | $5.05 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $18.42 | $19.97 | $21.77 | $20.88 |
| Total cash flows from operations | -$96.07 | -$39.86 | -$133.25 | $8.8 |
| Investing activities | ||||
| Capital expenditures | -$0.74 | -$2.12 | -$3.56 | -$3.06 |
| Investments | -$80.72 | $124.47 | $221.98 | $120.89 |
| Total cash flows from investing | -$81.45 | $121.35 | $216.92 | $117.83 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $38.94 | $1.56 | $16.77 | $5.4 |
| Net borrowings | ||||
| Total cash flows from financing | $38.94 | $1.56 | $16.77 | $5.4 |
| Effect of exchange rate | $0.06 | -$0.05 | $0.03 | $0.03 |
| Change in cash and equivalents | -$138.53 | $83 | $100.47 | $132.06 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$153.61 | -$650.17 | $377.66 | -$348.87 |
| Operating activities | ||||
| Depreciation | $19.84 | $24.17 | $17.95 | $9.18 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $81.03 | $97.95 | $102.39 | $66.02 |
| Total cash flows from operations | -$260.38 | -$495.74 | $538.97 | -$238.37 |
| Investing activities | ||||
| Capital expenditures | -$9.47 | -$37.19 | -$81.7 | -$18.36 |
| Investments | $386.62 | -$221.47 | -$953.73 | -$522.81 |
| Total cash flows from investing | $374.65 | -$258.65 | -$1035.43 | -$541.17 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $62.66 | $38.59 | $250.94 | $1016.15 |
| Net borrowings | ||||
| Total cash flows from financing | $62.66 | $38.59 | $250.94 | $1016.15 |
| Effect of exchange rate | $0.07 | -$0.08 | -$0.01 | $0.04 |
| Change in cash and equivalents | $177.01 | -$715.88 | -$245.52 | $236.66 |
News
Fundamentals
| Market cap | $4.50B |
|---|---|
| Enterprise value | $4.33B |
| Shares outstanding | 80.04M |
| Revenue | $371.21M |
|---|---|
| EBITDA | -$130.88M |
| EBIT | -$150.72M |
| Net Income | -$153.61M |
| Revenue Q/Q | 3.35M% |
| Revenue Y/Y | 30.89K% |
| P/E ratio | -29.26 |
|---|---|
| EV/Sales | 11.67 |
| EV/EBITDA | -33.10 |
| EV/EBIT | -28.75 |
| P/S ratio | 12.11 |
| P/B ratio | 2.39 |
| Book/Share | 23.50 |
| Cash/Share | 5.01 |
| EPS | -$1.92 |
|---|---|
| ROA | -7.02% |
| ROE | -8.44% |
| Debt/Equity | 0.18 |
|---|---|
| Net debt/EBITDA | 0.41 |
| Current ratio | 17.54 |
| Quick ratio | 17.54 |